| Dr Stephanie Ann Schultz, OD | |
|
112 Bramble Bush Rd, Coventry, RI 02816-4904 | |
| (401) 397-2597 | |
| Not Available |
| Full Name | Dr Stephanie Ann Schultz |
|---|---|
| Gender | Female |
| Speciality | Optometry |
| Experience | 17 Years |
| Location | 112 Bramble Bush Rd, Coventry, Rhode Island |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891985149 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | ODTG00520 (Rhode Island) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Robert E Miller Od Pc | 8820221005 | 2 |
News Archive
Researchers in the United States have found that drinking coffee does not increase the risk of heart attacks in women.
Fred Hutchinson Cancer Research Center has received a pledge of $10 million to advance the promising field of immunotherapy research to treat and cure cancer, even in late stages.
Teva Pharmaceutical Industries Ltd. today announced results from the Phase II ALSTAR trial. The trial was designed to assess efficacy, safety and tolerability of Talampanel (a selective AMPA antagonist) in reducing disease-related functional deterioration in Amyotrophic Lateral Sclerosis patients.
UCLA biophysicists have developed a new method to rapidly determine a single cell's stiffness and size - which could ultimately lead to improved treatments for cancer and other diseases.
Takeda Pharmaceutical Company Limited and Natrogen Therapeutics International, Inc. jointly announced today an agreement whereby Takeda will acquire an exclusive license to develop Natrogen's Natura-alpha compound as well as an option to acquire Natrogen. Natura-alpha is a synthetic small molecule oral compound that is believed to inhibit pro-inflammatory cytokine expression, which may help to reduce gastrointestinal inflammation. Natura-alpha is currently in Phase 2 development for the treatment of ulcerative colitis.
› Verified 5 days ago
| Provider Name | Robert E Miller Od Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1275767527 PECOS PAC ID: 8820221005 Enrollment ID: O20140424001408 |
News Archive
Researchers in the United States have found that drinking coffee does not increase the risk of heart attacks in women.
Fred Hutchinson Cancer Research Center has received a pledge of $10 million to advance the promising field of immunotherapy research to treat and cure cancer, even in late stages.
Teva Pharmaceutical Industries Ltd. today announced results from the Phase II ALSTAR trial. The trial was designed to assess efficacy, safety and tolerability of Talampanel (a selective AMPA antagonist) in reducing disease-related functional deterioration in Amyotrophic Lateral Sclerosis patients.
UCLA biophysicists have developed a new method to rapidly determine a single cell's stiffness and size - which could ultimately lead to improved treatments for cancer and other diseases.
Takeda Pharmaceutical Company Limited and Natrogen Therapeutics International, Inc. jointly announced today an agreement whereby Takeda will acquire an exclusive license to develop Natrogen's Natura-alpha compound as well as an option to acquire Natrogen. Natura-alpha is a synthetic small molecule oral compound that is believed to inhibit pro-inflammatory cytokine expression, which may help to reduce gastrointestinal inflammation. Natura-alpha is currently in Phase 2 development for the treatment of ulcerative colitis.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Stephanie Ann Schultz, OD 112 Bramble Bush Rd, Coventry, RI 02816-4904 Ph: (401) 397-2597 | Dr Stephanie Ann Schultz, OD 112 Bramble Bush Rd, Coventry, RI 02816-4904 Ph: (401) 397-2597 |
News Archive
Researchers in the United States have found that drinking coffee does not increase the risk of heart attacks in women.
Fred Hutchinson Cancer Research Center has received a pledge of $10 million to advance the promising field of immunotherapy research to treat and cure cancer, even in late stages.
Teva Pharmaceutical Industries Ltd. today announced results from the Phase II ALSTAR trial. The trial was designed to assess efficacy, safety and tolerability of Talampanel (a selective AMPA antagonist) in reducing disease-related functional deterioration in Amyotrophic Lateral Sclerosis patients.
UCLA biophysicists have developed a new method to rapidly determine a single cell's stiffness and size - which could ultimately lead to improved treatments for cancer and other diseases.
Takeda Pharmaceutical Company Limited and Natrogen Therapeutics International, Inc. jointly announced today an agreement whereby Takeda will acquire an exclusive license to develop Natrogen's Natura-alpha compound as well as an option to acquire Natrogen. Natura-alpha is a synthetic small molecule oral compound that is believed to inhibit pro-inflammatory cytokine expression, which may help to reduce gastrointestinal inflammation. Natura-alpha is currently in Phase 2 development for the treatment of ulcerative colitis.
› Verified 5 days ago
Dr. Richard S Liner, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 860 Tiogue Ave, Coventry, RI 02816 Phone: 401-828-2020 Fax: 401-828-4482 | |
Dr. Mark G Blasbalg, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1193 Tiogue Ave, Coventry, RI 02816 Phone: 401-823-8200 Fax: 401-826-8708 | |
Liane Carley Prytula, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1193 Tiogue Ave, Coventry, RI 02816 Phone: 401-823-8200 | |
Coventry Eye Care Associates & Optical Center Optometrist Medicare: Medicare Enrolled Practice Location: 860 Tiogue Ave, Coventry, RI 02816 Phone: 401-828-2020 Fax: 401-828-4482 | |
Acuity Vision & Eyewear Center Optometrist Medicare: Medicare Enrolled Practice Location: 1193 Tiogue Ave, Coventry, RI 02816 Phone: 401-823-8200 Fax: 401-826-8708 | |
Teresa N Head, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1193 Tiogue Ave, Coventry, RI 02816 Phone: 401-823-8200 |